A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

    Not Recruiting
  • End date
    Jul 12, 2022
  • participants needed
  • sponsor
    Nektar Therapeutics
Updated on 1 August 2021
measurable disease
systemic chemotherapy
metastatic urothelial carcinoma


The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.

Condition urinary tract neoplasm, Metastasis, bladder cancer, bladder disorder, Liver Metastases, Bone Metastases, Brain Metastases, Urothelial Cancer, Metastatic Cancer, Bladder Disorders, Neoplasm Metastasis, Bladder Carcinoma, Urologic Cancer
Treatment Nivolumab, NKTR-214, Reference Gemcitabine, Reference Carboplatin, bempegaldesleukin
Clinical Study IdentifierNCT03785925
SponsorNektar Therapeutics
Last Modified on1 August 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note